Compare VTRS & PNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTRS | PNR |
|---|---|---|
| Founded | 1961 | 1966 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.8B | 17.6B |
| IPO Year | N/A | N/A |
| Metric | VTRS | PNR |
|---|---|---|
| Price | $14.28 | $95.20 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 14 |
| Target Price | $11.83 | ★ $116.62 |
| AVG Volume (30 Days) | ★ 8.7M | 2.3M |
| Earning Date | 02-26-2026 | 02-03-2026 |
| Dividend Yield | ★ 3.35% | 1.14% |
| EPS Growth | N/A | ★ 5.81 |
| EPS | N/A | ★ 3.96 |
| Revenue | ★ $14,124,400,000.00 | $4,176,000,000.00 |
| Revenue This Year | N/A | $5.05 |
| Revenue Next Year | $1.25 | $4.42 |
| P/E Ratio | ★ N/A | $24.01 |
| Revenue Growth | N/A | ★ 2.28 |
| 52 Week Low | $6.85 | $74.25 |
| 52 Week High | $14.50 | $113.95 |
| Indicator | VTRS | PNR |
|---|---|---|
| Relative Strength Index (RSI) | 74.35 | 32.07 |
| Support Level | $12.92 | $92.92 |
| Resistance Level | $14.50 | $107.59 |
| Average True Range (ATR) | 0.33 | 3.05 |
| MACD | 0.08 | -1.27 |
| Stochastic Oscillator | 88.72 | 13.91 |
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Its business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.1 billion in revenue in 2024.